Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease
NCT01988701 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2015-03-02
Summary
This research trial studies lymphocyte profiles and activation status in patients with graft-versus-host disease. Studying samples of blood in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to graft-versus-host disease.
Conditions
- Graft Versus Host Disease
- Hematopoietic/Lymphoid Cancer
Interventions
- OTHER
-
Ancillary-Correlative
Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
Sponsors & Collaborators
-
Ohio State University Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Samantha Jaglowski, MD · Ohio State University Comprehensive Cancer Center
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-02-28
- Primary Completion
- 2016-12-31
More Related Trials
-
Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease
NCT00058773 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
NCT01232556 ·Status: TERMINATED ·Phase: PHASE3
-
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma
NCT00383097 ·Status: TERMINATED ·Phase: PHASE1
-
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
NCT00005631 ·Status: COMPLETED ·Phase: PHASE2
-
Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
NCT00176501 ·Status: TERMINATED ·Phase: PHASE2
-
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00008021 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
NCT06670105 ·Status: WITHDRAWN ·Phase: PHASE2
-
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma
NCT01490801 ·Status: COMPLETED
-
Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma
NCT01366157 ·Status: COMPLETED
-
Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant
NCT02109809 ·Status: TERMINATED ·Phase: NA
-
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
NCT00141700 ·Status: TERMINATED ·Phase: PHASE2
-
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
NCT01636388 ·Status: TERMINATED ·Phase: PHASE2
-
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT06675123 ·Status: RECRUITING ·Phase: PHASE1
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
NCT00971763 ·Status: COMPLETED ·Phase: PHASE2
-
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
NCT04858256 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
NCT00143871 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
NCT01007292 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
NCT00368082 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
NCT02038933 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
NCT00867529 ·Status: COMPLETED ·Phase: PHASE2
-
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
NCT00455897 ·Status: TERMINATED ·Phase: PHASE2
-
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
NCT01206777 ·Status: COMPLETED ·Phase: PHASE2
-
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
NCT01318317 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
NCT00398177 ·Status: RECRUITING